Skip to content
MARKETS / NASDAQ / LFCR
NASDAQ · PHARMACEUTICAL PREPARATIONS · MID CAP

Lifecore Biomedical, Inc. \de\ LFCR

16 fiscal years on record · USD · FY2024 reported · SEC filings only
$128.9M
▲ 0.5% YoY
$-38.7M
▼ 422.3% YoY
$-13.6M
In brief

What this company does

Lifecore Biomedical, Inc., located in Chaska, Minnesota, is a contract development and manufacturing organization that provides development, cGMP manufacturing and aseptic filling of complex formulations and highly viscous sterile injectable pharmaceutical drug and medical device products in syringes, vials and cartridges, across a wide variety of modalities. It also manufactures hyaluronic acid in bulk form as well as in formulated and filled syringes and vials for customers' injectable products used in treating medical conditions and procedures, including ophthalmic and orthopedic applications. It operates three facilities with a combined 250,000 square feet in Chaska, Minnesota, located within two miles of one another and regulated under one FDA establishment identifier number. As of May 25, 2025, the company had 406 full-time employees, all located in the United States, none of whom were represented by labor unions or collective bargaining agreements. The company's chief operating decision maker manages its CDMO and HA manufacturing operations on the basis of a single integrated segment. The company was incorporated under the laws of the State of Delaware under its prior corporate name in 2007. Lifecore's predecessor business commenced in the mid-1960s with a primary focus on microbial diagnostic devices, and it developed its HA capabilities in the early 1980s. In 2022, it changed its corporate name from Landec Corporation to Lifecore Biomedical, Inc.

Written from the business description in Lifecore Biomedical, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 7 August 2025. Every sentence was checked against that document before publication.

Growth
USD 128.9M
Revenue, FY2024 · full 16-year series below
Revenue $M Net income $M
FY2024 · Revenue 128.9 · Net income -38.7
200M400M-40M-80M200920112013201520172019202120232024
Compound annual growth
+5.0%
−4.2%
−13.3%
−4.0%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −4.2% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−30 cents
lost on every revenue dollar
Operating margin Net margin
FY2024 · Operating -13.4% · Net -30.0%
-50%-100%200920112013201520172019202120232024
ROE
FY2024 · ROE -612.1%
100%200%300%-200%-400%-600%200920112013201520172019202120232024

Each USD of equity lost 612 cents this year.

Cash & shareholders
returned in FY2024 · dividends + net buybacks
Free cash flow $M
FY2024 · FCF -13.6
8M16M-20M-40M200920112013201520172019202120232024
Net buybacks $M Dividends $M
FY2011 · Dividends — · Net buybacks 4.9
2M4M20102011

Total assetsUSD 239.3M
EquityUSD 1.3M
CashUSD 8.3M
Gross debtUSD 133.9M
Net debtUSD 125.6M
Current ratio2.84×

Net debt stands at 9402% of equity.

The 16-year record
16 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 2024202320222021202020192018201720162015201420132012201120102009
Revenue $B0.10.10.10.10.10.20.60.50.50.50.50.50.40.30.30.2
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.00.00.00.0−0.00.00.00.00.00.00.0
EBITDA $B−0.0−0.0−0.00.00.0−0.00.00.00.0−0.00.00.00.00.00.00.0
Income tax $B0.00.00.0−0.0−0.0−0.00.0−0.00.0−0.00.00.00.00.00.0−0.0
Net income $B−0.00.0−0.1−0.1−0.0−0.00.00.00.0−0.00.00.00.00.00.00.0
Free cash flow $B−0.0−0.0·−0.0−0.0−0.0−0.0−0.00.0−0.00.00.00.00.00.00.0
EPS, diluted $−1.270.33−3.32−3.97−1.10−1.310.010.890.38−0.430.500.710.850.490.150.15
Dividend / sh $················
Payout %················
ROE %−612.1339.1−238.2−80.6−15.0−15.30.210.44.8−5.46.410.013.88.92.9·
Shares out B0.040.030.030.030.030.030.030.030.030.030.030.030.030.030.03·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 78 reconciliationsAUDITED

Reconciled in 16 of 19 fiscal years. 17 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsMay 25
SEC categorysmaller reporting company
Data on record since2009

Share this section

Download image